RT Journal Article
SR Electronic
T1 Diagnostic performance of host protein signatures as a triage test for active pulmonary TB
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.31.23285229
DO 10.1101/2023.01.31.23285229
A1 Koeppel, Lisa
A1 Denkinger, Claudia M
A1 Wyss, Romain
A1 Broger, Tobias
A1 Chegou, Novel N
A1 Dunty, Jill M
A1 Scott, Kerry
A1 Cáceres, Tatiana
A1 Dutoit, Elloise
A1 Ugarte-Gil, Cesar
A1 Nicol, Mark
A1 Gotuzzo, Eduardo
A1 Corstjens, Paul L A M
A1 Geluk, Annemieke
A1 Sigal, George B
A1 Moreau, Emmanuel
A1 Albertini, Audrey
A1 Mantsoki, Anna
A1 Ongarello, Stefano
A1 Walzl, Gerhard
A1 Fernandez Suarez, Marta
YR 2023
UL http://medrxiv.org/content/early/2023/02/01/2023.01.31.23285229.abstract
AB The current four symptom screen recommended by the WHO is widely used as screen to initiate diagnostic testing for active pulmonary tuberculosis (TB), yet the performance is poor especially when TB prevalence is low. In contrast, more sensitive molecular tests are less suitable for the placement at primary care level in low resource settings. In order to meet the WHO End TB targets new diagnostic approaches are urgently needed to find the missing undiagnosed cases. Proteomics-derived blood host biomarkers have been explored because protein detection technologies are suitable for the point-of-care setting and could meet cost targets.This study aims to find a biomarker signature that fulfills WHO’s target product profile (TPP) for a TB screening. 12 blood-based protein biomarkers from three sample populations (Vietnam, Peru, South Africa) are analyzed individually and in combinations via advanced statistical methods and machine learning algorithms. The combination of I-309, SYWC and kallistatin shows the most promising results for TB prediction throughout the datasets meeting the TPP for a triage test in adults from two countries (Peru and South Africa). The top performing individual markers identified at the global level (I-309 and SYWC) were also among the best performing markers at country level in South Africa and Vietnam.This analysis clearly shows that a host protein biomarker assay is feasible in adults for certain geographical regions based on one or two biomarkers with a performance that meets minimal WHO TPP criteria.Abstract Importance Tuberculosis (TB) remains a serious worldwide health problem and diagnosis is hampered by the complexity of tests at primary care level in low resource settings or the low accuracy for screening settings. In order to meet the WHO End TB targets new diagnostic approaches are urgently needed to find the missing undiagnosed cases.This analysis clearly shows that a host protein biomarker assay is feasible in adults for certain geographical regions. We were able to construct an algorithm through statistical methods and machine learning algorithms whose performance meets the minimum of the WHO target product profile criteria. Thus, further work should be addressed at demonstrating that such as assay can be translated into a practical point-of-care test, and to better understand how to address regional differences in biomarker levels and responses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGovernment of the Netherlands to FIND DPDP15O64DW2UAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approvals for the study were obtained by the Human Research Ethics Committee of the respective sites including the Vietnam Committee of the Ministry of Health, the City of Cape Town as well as the University of Cape Town Human Research Ethics Committee and the Ethics Committee of the Universidad Peruana Cayetano Heredia. The study was undertaken in accordance with the principles of the Helsinki Declaration. Informed consent was obtained from patients who agreed to participate.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors